AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04644289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: durvalumab
Description: Durvalumab is administered 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle) .
Study NCT06614309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Progressive Carbon Dioxide
Description: The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.
Study NCT06541119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy programme
Description: * Passive abduction of the Hallux with traction~* short foot exercise~* toe spread outs
Study NCT05175729 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Ophthalmologic Examination
Description: Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
Study NCT04827875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001
Description: Intradermal
Study NCT06285331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Bed
Description: The automatic bed is controlled by a screen and allows clinicians to perform passive leg raising on patients without touching them physically.
Study NCT06285331 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Manual
Description: The clinicians will perform passive leg raising on patients by touching their legs physically.
Study NCT04971421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA - circulating tumor DNA
Description: lcWGS and WGS of circulating tumor DNA
Study NCT04971421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TEP - Tumor Educated Platelets
Description: sequencing miRNA from TEPs
Study NCT05038943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paragonix SherpaPak Cardiac Transport System
Description: Transportation of cardiac allografts in a device maintaining constant optimal temperature to minimize freezing tissue injury
Study NCT05069610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD17002
Description: A recombinant protein
Study NCT05069610 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Formulation buffer)
Description: Formulation buffer
Study NCT05968131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: The control group will receive only strength training intervention included the following components:~Range Of Motion Exercises: movements to the extent possible of the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion-eversion) and toe (flexion-extension).~5 repetitions of each ROM exercise will be done for 2 minutes. Muscle Strengthening Exercises: active movements against resistance (using a Thera band) at the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion- eversion) and toe (flexion-extension).~Each Strengthening exercise will be performed for 5 minutes with 10 repetitions.
Study NCT05968131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: The control group will receive only strength training intervention included the following components:~Range Of Motion Exercises: movements to the extent possible of the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion-eversion) and toe (flexion-extension).~5 repetitions of each ROM exercise will be done for 2 minutes. Muscle Strengthening Exercises: active movements against resistance (using a Thera band) at the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion- eversion) and toe (flexion-extension).~Each Strengthening exercise will be performed for 5 minutes with 10 repetitions.
Study NCT05968131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy with Proprioceptive Training Exercises
Description: Interventional group will receive strengthening intervention as well as proprioceptive training for 32 sessions. ROM and Strengthening exercise will be performed same as in control group.~Exercises For Proprioceptive Training: Intervention group will practice an additional 24 minutes of proprioceptive training (two minutes rest prior to performing this training). A circuit with different floor texture composed of 6 stations of exercises to stimulate the sole of foot where participant had to improve gait by stepping with alternate feet marker placed on ground and progression will be done by modify the speed and direction. Material used to build the circuit are in following order: 10 cm thick foam, a wood box with beans, a 2 cm thick mat with density lower than foam, a wooden box filled with sand, balance board to train the lateral balance reactions, a wooden box filled with cotton. Duration of this training is 24 minutes; patient will spend 4 minutes on each station.
Study NCT05244993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105: 100mg per bottle, 200mg IV Day 1, cycled every 21 days
Study NCT05244993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib Hydrochloride: 12mg per capsule, 12 mg PO once daily on Days 1-14, cycled every 21 days
Study NCT05244993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: Albumin paclitaxel: 100mg per bottle, 125mg/m2 IV Days 1, 8, cycled every 21 days
Study NCT06306820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed PEEP
Description: Patients will receive a fixed positive end-expiratory pressure (PEEP) of 5 cmH2O throughout the surgical procedure.
Study NCT06306820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lung recruitment
Description: Patients will receive ultrasound-guided lung before pneumoperitoneum, after pneumoperitoneum then once an hour, until the end of surgery. Alveolar recruitment will be conducted the same as that for the conventional manoeuvre with a simultaneous continuous ultrasound assessment if atalectasis is detected until no collapsed areas are visualized. When the collapsed lung areas are absent on the sonogram, positive end-expiratory pressure (PEEP) can no longer increase at this point. Subsequently, the pressure will be maintained for approximately 10 breaths.
Study NCT06306820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized PEEP
Description: Patients will receive individualized positive end-expiratory pressure (PEEP). After the first recruitment Maneuvere (RM), titration of PEEP will be performed by setting the initial PEEP to 5 cm H2O, then increasing PEEP according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing PEEP, until the calculated Cstat shows a downward trend, the we set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEP for this patient. The highest PEEP is limited to 15 cmH2O.
Study NCT05342935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inteligent Dialysis Assistant (IDA)
Description: The IDA is a small dialysis system that allows a higher level of freedom to the patients, permitting them to perform the PD exchange while continuing to do their everyday activities
Study NCT06314867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 1)
Description: All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112011), intramuscularly injected into the lateral deltoid muscle of the upper arm.
Study NCT06314867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 2)
Description: All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112012), intramuscularly injected into the lateral deltoid muscle of the upper arm.
Study NCT06314867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 3)
Description: All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112013), intramuscularly injected into the lateral deltoid muscle of the upper arm.
Study NCT04991259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT)
Description: Continuous renal replacement therapy will be administered as continuous venovenous hemodiafiltration (CVVHDF) using Prisma and Prismaflex (Gambro) devices, with blood flows ranging from 150-180 mL/hr and target effluent rates of 20 - 25 mL/kg/hr. Anticoagulation was not used during dialysis. CRRT would be continued until resolution of cerebral edema and in decrease in ammonia levels below 150 ug/dl or in those who develop adverse effects of therapy.
Study NCT04991259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Renal Replacement Therapy (CRRT)
Description: Continuous renal replacement therapy will be administered as continuous venovenous hemodiafiltration (CVVHDF) using Prisma and Prismaflex (Gambro) devices, with blood flows ranging from 150-180 mL/hr and target effluent rates of 20 - 25 mL/kg/hr. Anticoagulation was not used during dialysis. CRRT would be continued until resolution of cerebral edema and in decrease in ammonia levels below 150 ug/dl or in those who develop adverse effects of therapy.
Study NCT04991259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: In the L- ICU, patients will be managed by a multidisciplinary team. Intubation and ventilation will be undertaken for standard indications in addition to the development of grade 3 encephalopathy or evidence of cerebral edema on CT-scan. Fluid management will be done with crystalloids, with the use of colloids (5% albumin) in patients with severe hypoalbuminemia (serum albumin less than 2.5gm/dl). Norepinephrine will be the primary vasopressor used to target a mean arterial pressure of 65-70 mm of Hg. with adjunctive use of intravenous low dose hydrocortisone and vasopressin in patients not responsive to initial therapy.
Study NCT05811728 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: The low-level laser applied will be a Diode laser\* emitting infrared radiation at a wavelength of 980 nm, in a continuous mode. On the experimental side, subjects will receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter, till the termination of the study period (3 months).
Study NCT05811728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: without beam emission
Description: The laser tip will be held passively on the control side without beam emission, providing a placebo effect.
Study NCT05769842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1\~2mg/kg before extubation when the patient recovered spontaneously.
Study NCT05769842 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: normal saline
Description: Same dose as propofol.
Study NCT05549141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill gait training with gait facilitators
Description: 6 sessions of 30 minutes each of treadmill gait training with functional electrical stimulation as a gait facilitator
Study NCT06614309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.
Study NCT04990791 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 75mg
Description: Aspirin 75mg OD for 14 days
Study NCT04990791 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 20mg
Description: Aspirin 20mg BD for 14 days
Study NCT04990791 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban 2.5 mg
Description: Rivaroxaban 2.5mg BD
Study NCT05549141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treadmill gait training not-associated with gait facilitators
Description: 6 sessions of 30 minutes each of treadmill gait training
Study NCT04655105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: root canal rotary files
Description: post operative pain evaluation using different rotary file system
Study NCT04655105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: root canal rotary files
Description: post operative pain evaluation using different rotary file system
Study NCT06342726 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAX Warming Blanket
Description: Electric resistive active external warming blanket
Study NCT06342726 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive insulation
Description: 3-layered wrapping model
Study NCT06342726 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Passive insulation
Description: 3-layered wrapping model
Study NCT05996731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.
Study NCT05996731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.
Study NCT06614309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training: Progressive Carbon Dioxide Ramping
Description: Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the progressive CO2 ramp protocol of 60-minute sessions, which will include 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles, for every visit during the 14 days.
Study NCT06614309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training: Intermittent Hypoxic Exposure
Description: Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the intermittent hypoxia exposure protocol of 60-minute sessions, which will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air for every visit during the 14 days.
Study NCT06614309 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training: Placebo Control
Description: Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days.
Study NCT06616558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen SPF 70
Description: Participants will topically apply sunscreen SPF 70
Study NCT06616558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen SPF 70
Description: On the randomized side of the half-face, the product will be applied by a qualified technician
Study NCT06616792 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dexamethasone phonophoresis
Description: Ultrasound therapeutic device with the use of 0.4% Dexamethasone sodium phosphate gel for phonophoresis.
Study NCT06616792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Description: low level laser therapy placed in contact with the skin perpendicular over the body acupoints (LI 4) - (LI 20) - (EX- HN5) - (GV 20) - (GV 24) - (ST3) - (ST 7) in both sides and on (EX-HN3) acupoint,
Study NCT06616792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional medication
Description: Each participant in this group receive the traditional medication.
Study NCT06616792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional medication
Description: Each participant in this group receive the traditional medication.
Study NCT06677827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25% only bilateral
Study NCT06677827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate and Bupivacaine 0.125%
Description: External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25%+200 mg magnesium sulphate bilateral
Study NCT06677658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Olive Oil
Description: Group 1 included patients who consumed at least 20 ml of oral olive oil daily. Group 2 included patients who did not consume olive oil.
Study NCT06677658 — intervention group
Intervention type: DRUG
Intervention: Methylprednisolone
Description: Both groups were diagnosed with Covid-19 pneumonia and were given pulse steroid ( methylprednisolone ) treatment at 250 mg/day for 3 days.
Study NCT04522804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
Study NCT05373641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated feedback
Description: Repeated feedback monthly based on previous month pain documentation audit results.
Study NCT05373641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain documentation audit
Description: Monthly pain documentation audit
Study NCT05373641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain documentation audit
Description: Monthly pain documentation audit
Study NCT05744011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tango intervention
Description: The interventions will be implemented by ABB Reportages and will be carried out by nursing staff who had previously received training in therapeutic tango at the University of Burgundy.~A dance movement therapist and a musician will accompany the interventions twice a month.~Participants will attend a 1-hour tango session, twice a week for twelve weeks.
Study NCT05744011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Physical Activity
Description: The intervention will be carried out by an Adapted Physical Activity professor and by nursing staff.~Music is prohibited during the sessions. Participants will attend a 1-hour APA, twice a week for twelve weeks.
Study NCT05594056 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transorbital ultrasound of the optic nerve sheet
Description: Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).
Study NCT05594056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transorbital ultrasound of the optic nerve sheet
Description: Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).
Study NCT05263375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovalve TMVR system
Description: Innovalve TMVR system
Study NCT05651139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Vibration Device
Description: An electrical Vibration Massage device will be used to induce deep tissue vibration stimulation
Study NCT05545059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Description: In sacubitril/valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, sacubitril/valsartan 200mg to treat. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
Study NCT04741711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.
Description: An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.
Study NCT04741711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual care without ultrasound guidance
Description: Usual care (i.e. without ultrasound guidance)